ClinicalTrials.gg
RecruitingNCT05927818Updated Nov 18, 2026

Sentinel Lymph Node Biopsy in Early-Stage Ovarian Cancer

An interventional study of Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer in Sentinel Lymph Node and Ovarian Carcinoma, sponsored by Istanbul University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Istanbul University · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Apr 2023; still recruiting 3 years 7 months later.
Updated Nov 18, 2026First site in Turkey (Türkiye)No longer in Turkey+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 33 studies in Ovarian Neoplasms with a site in Turkey — 7 open to participants now, 15 under way, 8 of them phase 3. Ovarian Neoplasms · Turkey.

Planned enrollment
23rd of 28
100 · median 382
Started
2023
with 4 others
No phase
5 of 33
1 open now
Primary completion
2028-06
later than 10 of 14 live
Registered
25th of 33
by date
Lead sponsor
2 of 33
Istanbul University

Among the 33 studies in Ovarian Neoplasms with a site in Turkey, this one is the 23rd largest by planned enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2023, is one of 5 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 25th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

7 of the 33 studies in Ovarian Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 90 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Ovarian Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing it to the results obtained from systematic lymphadenectomy, each performed in participants with a suspicious adnexal mass for early-stage ovarian cancer.

Read the detailed description

Ovarian cancer is the leading cause of mortality among gynecologic cancers. Although most women are diagnosed at advanced stage, about 20% are can be diagnosed at an earlier stage. Treatment and prognosis depends on the correct assessment of stage of the apparently early stage (Stage I and II). About 10-30% of apparently early stage ovarian cancer patients are upstaged based on the final pathology report. Detection of positive lymph node is an important contributor for upstaging of apparently early stage ovarian cancer. However, systematic lymphadenectomy carries immediate and long term risks for patients including bleeding, massive transfusions, prolongation of operation time, serious major vessel and major abdominal organ injury and death. These risks are especially increased in paraaortic lymphadenectomy which is an integral part of staging procedure in early ovarian cancer.

Sentinel lymph node biopsy (SLNB) procedure is the biopsy of one or two lymph node(s) which represents the lymph node basin draining the area of malignancy. This biopsy may potentially eliminate the need systemic pelvic / paraaortic lymphadenectomy. Although SLNB became an integral and accepted procedure in endometrium and cervix cancers, available data on the SLNB for ovarian cancer is limited and is in its infancy to be incorporated in routine practice of ovarian cancer surgery.

So, investigators aim to compare the effectiveness of SLNB procedure results with systematic lymphadenectomy, both performed in each participant, either by laparotomy or laparoscopy.

Technically, 2-4 mL of sterile black carbon stain is carefully injected beneath the adnexal mass just under peritoneal covering of mesovarium or infundibulopelvic ligament avoiding intravascular injection before removal of suspicious adnexal mass for frozen section. This is done classically through a laparotomy incision but can also be performed laparoscopically via a needle introduced transcutaneously into the base of adnexa under optical supervision. 10-15 minute interval is allowed before resection of adnexal mass for frozen section. A peritoneal incision and pelvic and paraaortic retroperitoneal dissection is carried out for identification of major vessels and important surgical landmarks (abdominal ureters, gonadal vessels, inferior mesenteric artery and etc.) up to the left renal vein to visually detect the sentinel lymph node(s) stained in black. Lymphatic vessels are carefully eliminated visually not to be biopsied instead of sentinel lymph node. An additional 2 mL injection is allowed if a SLN could not be detected before systematic lymphadenectomy, adnexectomy and other surgical staging procedures. Frozen section of a adnexal mass is carried out thereafter following the detection and biopsy of SLN. Systematic lymphadenectomy is abandoned in case of a non-malignant frozen section result.

03

Conditions studied

  • Sentinel Lymph Node
  • Ovarian Carcinoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must have a suspicious adnexal mass for early stage ovarian cancer

Must be medically and surgically fit enough to perform SLNB and complete the systematic lymphadenectomy.

-

Exclusion criteria

Exclusion Criteria:

Ovarian mass with low probability for early stage ovarian cancer.

Medical or surgical for surgical comprehensive staging.

cancers or double primary cancers (metachronous) of ovary

Recurrent ovarian cancer

Preoperative or intraoperative finding of advanced ovarian cancer (FİGO stage III and IV)

ovarian cancer

-

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Sentinel Lymph Node Biopsy and Systematic Lymph Node Dissection (Single Arm)

    This is a single arm interventional study in which the interventional and control arms are the same participant (each participant becomes its own control since the sentinel node biopsy- interventional arm - results are to be compared to systematic lymphadenectomy results-control arm). Intervention is injection of 2-4 mL sterile charcoal to the infundibulopelvic ligament or mesovarium of the suspicious adnexal mass followed by collection of stained sentinel lymph nodes and lymph nodes by systematic lymphadenectomy.

    Diagnostic Test: Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer

Interventions

  • Diagnostic testSentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer

    Described in previous sections

    Also known as: Systematic lymphadenectomy

06

What researchers measure

Primary outcomes

  1. Efficacy of sentinel lymph node biopsy in highly suspicious adnexal masses for early-stage ovarian cancer

    Sensitivity, specificity, positive and negative predictive value for sentinel lymph biopsy results (compared to lymph nodes collected by systemic lenfadenopathy) will be calculated. These calculations will be expressed in percentages and will be compared using appropriate statistical method.

    Time frame: From the day of surgery to final pathology report (two weeks)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Negishi H, Takeda M, Fujimoto T, Todo Y, Ebina Y, Watari H, Yamamoto R, Minakami H, Sakuragi N. Lymphatic mapping and sentinel node identification as related to the primary sites of lymph node metastasis in early stage ovarian cancer. Gynecol Oncol. 2004 Jul;94(1):161-6. doi: 10.1016/j.ygyno.2004.04.023. PubMed 15262135 ↗
  • Hassanzadeh M, Hosseini Farahabadi E, Yousefi Z, Kadkhodayan S, Zarifmahmoudi L, Sadeghi R. Lymphatic mapping and sentinel node biopsy in ovarian tumors: a study using intra-operative Tc-99m-Phytate and lymphoscintigraphy imaging. J Ovarian Res. 2016 Sep 7;9(1):55. doi: 10.1186/s13048-016-0265-4. PubMed 27604260 ↗
  • Uccella S, Nero C, Vizza E, Vargiu V, Corrado G, Bizzarri N, Ghezzi F, Cosentino F, Turco LC, Fagotti A, Scambia G. Sentinel-node biopsy in early-stage ovarian cancer: preliminary results of a prospective multicentre study (SELLY). Am J Obstet Gynecol. 2019 Oct;221(4):324.e1-324.e10. doi: 10.1016/j.ajog.2019.05.005. Epub 2019 May 10. PubMed 31082385 ↗
  • Lago V, Bello P, Montero B, Matute L, Padilla-Iserte P, Lopez S, Marina T, Agudelo M, Domingo S. Sentinel lymph node technique in early-stage ovarian cancer (SENTOV): a phase II clinical trial. Int J Gynecol Cancer. 2020 Sep;30(9):1390-1396. doi: 10.1136/ijgc-2020-001289. Epub 2020 May 23. PubMed 32448808 ↗
  • Vanneuville G, Mestas D, Le Bouedec G, Veyre A, Dauplat J, Escande G, Guillot M. The lymphatic drainage of the human ovary in vivo investigated by isotopic lymphography before and after the menopause. Surg Radiol Anat. 1991;13(3):221-6. doi: 10.1007/BF01627990. PubMed 1754957 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Jun 2028, 62 months after the start.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 62 months is above that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Oct 2025 → Jun 2028 and completion Jan 2026 → Aug 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jul 3, 2023
StartActual
Apr 15, 2023
Primary completionEst.
Jun 2028was Oct 2025
CompletionEst.
Aug 2028was Jan 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
Show site
  • Istanbul University · Istanbul, Turkey (Türkiye)
Show 1 removed
  • Istanbul University · Istanbul, Turkey
Nov 18, 2026
Primary completion
Oct 15, 2025→Jun 2028
Nov 18, 2026
Study completion
Jan 15, 2026→Aug 2028
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    1 site added, 1 site removed — first site in Turkey (Türkiye); no longer in Turkey
    Show site
    • Istanbul University · Istanbul, Turkey (Türkiye)
    Show 1 removed
    • Istanbul University · Istanbul, Turkey
    Primary completion Oct 15, 2025→Jun 2028
    Study completion Jan 15, 2026→Aug 2028
    + 3 other changes: verification date, oversight details and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05927818
Responsible party
Mustafa Albayrak (MD, Gynecologic Oncology Fellow, Istanbul University) — Principal investigator
First posted
Jul 3, 2023
Start date
Apr 15, 2023
Primary completion
Jun 2028 (estimated)
Completion
Aug 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Mustafa ALBAYRAK, MD
Contact
mustafaalbayrak@icloud.com
+90 532 687 10 51
Yagmur MİNARECİ, MD
Contact
yagmurminareci@gmail.com
+90 505 357 43 61

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion